DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
Alzheimer’s Disease – Current Treatment – Current Treatment: Physician Insights – Alzheimer’s Disease (US)
Alzheimer’s disease (AD) affects cognition and causes neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Disease-modifying therapy (DMT) is…
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Multiple System Atrophy – Epidemiology – Epidemiology – Multiple system atrophy – Mature Markets
Clarivate Epidemiology’s coverage of multiple system atrophy (MSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
